Expanding the antimicrobial spectrum of lugdunin: Discovery of multi-cationic derivatives of lugdunin with antimicrobial activity against gram-positive and gram-negative bacteria

Eur J Med Chem. 2025 Dec 5:299:118078. doi: 10.1016/j.ejmech.2025.118078. Epub 2025 Aug 20.

Abstract

Lugdunin, a newly discovered antibiotic with a unique structure, emerged during a decade-long antibiotic discovery void and is considered a promising lead for combating drug-resistant bacteria. However, its narrow spectrum targeting only Gram-positive bacteria and its structural limitations have hindered its development and clinical application. Herein, inspired by our previous combinatorial modification strategies for lugdunin, we designed and synthesized a series of multi-cationic lugdunin derivatives using a biphenylmethyl modification on the tryptophan indole structure combined with multi-cationic amino acid mutations, aiming to expand its antimicrobial spectrum. Our results showed that the optimized derivative, Lug-15, exhibited strong antibacterial activity against both Gram-positive and Gram-negative bacteria, including Escherichia coli and Pseudomonas aeruginosa. Lug-15 rapidly kills bacteria primarily through membrane disruption and had a very low propensity to induce bacterial resistance. Additionally, it demonstrated low hemolytic toxicity and significant therapeutic potential in various infection models, including keratitis caused by MRSA and P. aeruginosa, MRSA-induced pneumonia, thigh muscle infection, and wound infection, indicating Lug-15's broad-spectrum therapeutic potential. Therefore, this study overcomes the historical limitation of prior SAR attempts and offers a new lead for combating drug-resistant bacteria.

Keywords: Antibiotics; Antimicrobial resistance; In vivo therapeutic efficacy; Lugdunin; Membrane disruption.

MeSH terms

  • Animals
  • Anti-Bacterial Agents* / chemical synthesis
  • Anti-Bacterial Agents* / chemistry
  • Anti-Bacterial Agents* / pharmacology
  • Cations / chemistry
  • Cations / pharmacology
  • Dose-Response Relationship, Drug
  • Drug Discovery*
  • Gram-Negative Bacteria* / drug effects
  • Gram-Positive Bacteria* / drug effects
  • Humans
  • Mice
  • Microbial Sensitivity Tests
  • Molecular Structure
  • Peptides, Cyclic
  • Pseudomonas aeruginosa / drug effects
  • Structure-Activity Relationship
  • Thiazolidines

Substances

  • Anti-Bacterial Agents
  • Cations
  • lugdunin
  • Peptides, Cyclic
  • Thiazolidines